Shanghai Caerulum Pharma Discovery
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
CPI-444, also known as V81444, is an orally administered antagonist of the adenosine A2A receptor. Upon oral administration, CPI-444 binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment.